Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - mycophenolate mofetil - capsule, hard - 250 milligram(s) - selective immunosuppressants; mycophenolic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - mycophenolate sodium - gastro-resistant tablet - 180 milligram(s) - selective immunosuppressants; mycophenolic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - mycophenolate sodium - gastro-resistant tablet - 360 milligram(s) - selective immunosuppressants; mycophenolic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - mycophenolic acid - gastro-resistant tablet - 180 milligram(s) - selective immunosuppressants; mycophenolic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - mycophenolic acid - gastro-resistant tablet - 360 milligram(s) - selective immunosuppressants; mycophenolic acid

European Union - English - myHealthbox

genzyme therapeutics ltd - alemtuzumab - concentrate for solution for infusion - 12 mg alemtuzumab in 1.2 ml (10 mg/ml) - multiple sclerosis - selective immunosuppressants - indicated for adult patients with relapsing remitting multiple sclerosis (rrms) with active disease defined by clinical or imaging features

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - selective immunosuppressants - ulcerative colitisentyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.crohn’s diseaseentyvio is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

European Union - English - EMA (European Medicines Agency)

amgen europe bv - apremilast - arthritis, psoriatic; psoriasis - immunosuppressants - psoriatic arthritisotezla, alone or in combination with disease modifying antirheumatic drugs (dmards), is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior dmard therapy.psoriasisotezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-a light (puva).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - teriflunomide - tablet - 14mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - alemtuzumab - solution for infusion - 10mg/1ml